| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $2,064,135 | 14 | 67 |
Sells | $6,703,188 | 7 | 33 |
| Leonard Braden Michael | 10 percent owner | 1 | $1.56M | 2 | $2.87M | $-1.31M |
| Readnour Robin Shane | director | 7 | $405,521 | 0 | $0 | $405,521 |
| Easom Eric | Chief Executive Officer | 2 | $60,635 | 0 | $0 | $60,635 |
| Zakrzewski Joseph S | director | 3 | $27,846 | 0 | $0 | $27,846 |
| FitzPatrick Margaret M | director | 1 | $10,133 | 0 | $0 | $10,133 |
| Prior Stephen David | Chief Strategy Officer | 0 | $0 | 1 | $2,721 | $-2,721 |
| Chanda Sanjay | Chief Development Officer | 0 | $0 | 1 | $3,965 | $-3,965 |
| Day Lucy | Chief Financial Officer | 0 | $0 | 1 | $3,965 | $-3,965 |
| Eizen Joshua M | See Remarks | 0 | $0 | 1 | $12,958 | $-12,958 |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 0 | $0 | 1 | $3.81M | $-3.81M |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Over the last 12 months, insiders at AN2 Therapeutics, Inc. have bought $2.06M and sold $6.7M worth of AN2 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at AN2 Therapeutics, Inc. have bought $13.67M and sold $6.14M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $1.56M. Readnour Robin Shane (director) — $405,521. Easom Eric (Chief Executive Officer) — $60,635.
The last purchase of 10,000 shares for transaction amount of $10,665 was made by Easom Eric (Chief Executive Officer) on 2025‑06‑02.
| 2025-06-02 | Easom Eric | Chief Executive Officer | 10,000 0.0333% | $1.07 | $10,665 | +5.19% | ||
| 2025-05-30 | Sale | Leonard Braden Michael | 10 percent owner | 432,000 1.3646% | $1.01 | $436,477 | -4.91% | |
| 2025-05-28 | Sale | Leonard Braden Michael | 10 percent owner | 2.1M 7.0198% | $1.16 | $2.44M | -3.67% | |
| 2025-05-28 | FitzPatrick Margaret M | director | 8,610 0.0292% | $1.18 | $10,133 | -3.67% | ||
| 2025-01-03 | Sale | Eizen Joshua M | See Remarks | 9,663 0.0304% | $1.34 | $12,958 | -14.08% | |
| 2025-01-03 | Sale | Prior Stephen David | Chief Strategy Officer | 2,029 0.0064% | $1.34 | $2,721 | -14.08% | |
| 2025-01-03 | Sale | Day Lucy | Chief Financial Officer | 2,957 0.0093% | $1.34 | $3,965 | -14.08% | |
| 2025-01-03 | Sale | Chanda Sanjay | Chief Development Officer | 2,957 0.0093% | $1.34 | $3,965 | -14.08% | |
| 2024-12-10 | Readnour Robin Shane | director | 10,000 0.0329% | $1.49 | $14,930 | -17.22% | ||
| 2024-12-09 | Readnour Robin Shane | director | 30,772 0.104% | $1.43 | $43,984 | -11.97% | ||
| 2024-12-06 | Readnour Robin Shane | director | 19,228 0.0635% | $1.45 | $27,795 | -13.19% | ||
| 2024-11-27 | Readnour Robin Shane | director | 50,000 0.142% | $1.42 | $70,840 | -8.76% | ||
| 2024-11-27 | Zakrzewski Joseph S | director | 2,000 0.0056% | $1.40 | $2,800 | -8.76% | ||
| 2024-11-26 | Readnour Robin Shane | director | 25,000 0.0698% | $1.39 | $34,845 | -10.07% | ||
| 2024-11-20 | Readnour Robin Shane | director | 50,000 0.116% | $1.16 | $57,870 | -3.85% | ||
| 2024-11-19 | Readnour Robin Shane | director | 150,000 0.3112% | $1.04 | $155,258 | +18.40% | ||
| 2024-11-19 | Zakrzewski Joseph S | director | 5,000 0.0101% | $1.01 | $5,050 | +18.40% | ||
| 2024-11-18 | Easom Eric | Chief Executive Officer | 50,000 0.1001% | $1.00 | $49,970 | +25.00% | ||
| 2024-11-18 | Zakrzewski Joseph S | director | 20,000 0.0401% | $1.00 | $19,996 | +25.00% | ||
| 2024-08-14 | Leonard Braden Michael | 10 percent owner | 1.5M 3.1264% | $1.04 | $1.56M | +11.43% |
| Leonard Braden Michael | 10 percent owner | 3217432 10.6623% | $3.44M | 1 | 2 | |
| Readnour Robin Shane | director | 652573 2.1626% | $698,253.11 | 8 | 2 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 300853 0.997% | $321,912.71 | 9 | 1 | +12.48% |
| Easom Eric | Chief Executive Officer | 256380 0.8496% | $274,326.60 | 3 | 17 | |
| Zakrzewski Joseph S | director | 125199 0.4149% | $133,962.93 | 3 | 1 | |
| Eizen Joshua M | See Remarks | 116672 0.3866% | $124,839.04 | 0 | 1 | |
| Prior Stephen David | Chief Strategy Officer | 33313 0.1104% | $35,644.91 | 0 | 1 | |
| Day Lucy | Chief Financial Officer | 32670 0.1083% | $34,956.90 | 0 | 1 | |
| Chanda Sanjay | Chief Development Officer | 29824 0.0988% | $31,911.68 | 0 | 1 | |
| FitzPatrick Margaret M | director | 8610 0.0285% | $9,212.70 | 1 | 0 | |
| Shah Rajeev M. | 3773417 12.5048% | $4.04M | 5 | 0 | +11.29% | |
| Adjuvant Global Health Technology Fund DE, L.P. | 2210735 7.3262% | $2.37M | 1 | 0 | <0.0001% | |
| Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 377542 1.2511% | $403,969.94 | 1 | 10 | <0.0001% |
| Aziz Kabeer | director | 377542 1.2511% | $403,969.94 | 1 | 10 | <0.0001% |
| Krause Kevin Michael | Chief Strategy Officer | 1914 0.0063% | $2,047.98 | 0 | 2 |
$12,784,645 | 193 | 20.49% | $31.05M | |
$155,580,641 | 77 | -24.21% | $30.23M | |
$14,315,062 | 61 | -6.21% | $34.46M | |
$53,490,060 | 55 | 19.35% | $28.51M | |
$23,895,365 | 34 | -37.28% | $36.83M | |
$20,234,041 | 17 | 2.09% | $37.93M | |
AN2 Therapeutics, Inc. (ANTX) | $36,557,692 | 17 | 3.38% | $32.29M |
$17,594,514 | 16 | -20.37% | $28.9M | |
$156,484,110 | 12 | 52.55% | $27.38M | |
$19,300,035 | 11 | 45.88% | $33.53M | |
$31,978,951 | 10 | -70.03% | $34.3M | |
$149,996 | 5 | 16.26% | $39.64M | |
$147,504 | 5 | -36.70% | $27.26M | |
$1,184,658 | 4 | -22.17% | $28.52M | |
$67,369,250 | 3 | -22.09% | $37.63M | |
$157,740 | 3 | 153.95% | $33.95M | |
$100,266 | 2 | 3.17% | $28.29M | |
$150,000 | 1 | 5.48% | $32.89M | |
$500,000 | 1 | -22.94% | $26.82M |
| Increased Positions | 13 | +28.26% | 959,275 | +6.84% |
| Decreased Positions | 17 | -36.96% | 1M | -9.74% |
| New Positions | 5 | New | 111,098 | New |
| Sold Out Positions | 6 | Sold Out | 663,883 | Sold Out |
| Total Postitions | 42 | -8.7% | 14M | -2.9% |
| Bml Capital Management, Llc | $7,014.00 | 19.17% | 5.75M | 0 | 0% | 2024-12-31 |
| Almitas Capital Llc | $1,602.00 | 4.38% | 1.31M | +1M | New | 2024-12-31 |
| Vanguard Group Inc | $1,264.00 | 3.45% | 1.04M | -5,580 | -0.54% | 2024-12-31 |
| Peapod Lane Capital Llc | $709.00 | 1.94% | 580,853 | +2,028 | +0.35% | 2025-03-31 |
| Renaissance Technologies Llc | $707.00 | 1.93% | 579,773 | +155,973 | +36.8% | 2024-12-31 |
| Two Sigma Advisers, Lp | $645.00 | 1.76% | 528,300 | +407,400 | +336.97% | 2024-12-31 |
| Bank Of Montreal /Can/ | $515.00 | 1.41% | 422,077 | +422,077 | New | 2024-12-31 |
| Two Sigma Investments, Lp | $488.00 | 1.33% | 400,332 | +222,492 | +125.11% | 2024-12-31 |
| Bank Of Nova Scotia | $482.00 | 1.32% | 394,868 | +394,868 | New | 2024-12-31 |
| Bank Of America Corp /De/ | $470.00 | 1.29% | 385,475 | +369,265 | +2,278.01% | 2024-12-31 |